Hanmi Pharm Co Ltd
KRX:128940

Watchlist Manager
Hanmi Pharm Co Ltd Logo
Hanmi Pharm Co Ltd
KRX:128940
Watchlist
Price: 267 500 KRW 0.38%
Market Cap: 3.4T KRW
Have any thoughts about
Hanmi Pharm Co Ltd?
Write Note

Hanmi Pharm Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hanmi Pharm Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Hanmi Pharm Co Ltd
KRX:128940
Total Current Assets
â‚©721.5B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
3%
Yuhan Corp
KRX:000100
Total Current Assets
â‚©1.3T
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
6%
SK Biopharmaceuticals Co Ltd
KRX:326030
Total Current Assets
â‚©488.7B
CAGR 3-Years
4%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Hanmi Science Co Ltd
KRX:008930
Total Current Assets
â‚©286.8B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
2%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Total Current Assets
â‚©239B
CAGR 3-Years
12%
CAGR 5-Years
8%
CAGR 10-Years
10%
C
Celltrion Pharm Inc
KOSDAQ:068760
Total Current Assets
â‚©375.8B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
11%
No Stocks Found

Hanmi Pharm Co Ltd
Glance View

Market Cap
3.4T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Intrinsic Value
373 830.22 KRW
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Hanmi Pharm Co Ltd's Total Current Assets?
Total Current Assets
721.5B KRW

Based on the financial report for Sep 30, 2024, Hanmi Pharm Co Ltd's Total Current Assets amounts to 721.5B KRW.

What is Hanmi Pharm Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
3%

Over the last year, the Total Current Assets growth was -1%. The average annual Total Current Assets growth rates for Hanmi Pharm Co Ltd have been 1% over the past three years , 1% over the past five years , and 3% over the past ten years .

Back to Top